RESEARCH PAPER

Osteoarthritis: a Comprehensive Review Of Pathophysiology, Risk Factors, Prevention, And Management

Anjana singh[1] , Alka singh[2]

[1]BPT final year , Mangalayatan University Aligarh

[2]Assistant Professor, Department of Physiotherapy, Mangalayatan University Aligarh
Orcid Id:- 0009-0004-7861-9898

ABSTRACT

Osteoarthritis (OA) represents one of the most prevalent degenerative joint disorders worldwide, affecting millions of individuals and imposing substantial socioeconomic burdens on healthcare systems. This comprehensive review examines the multifaceted nature of osteoarthritis, exploring its underlying pathophysiological mechanisms, identifying key risk factors, and evaluating contemporary prevention strategies and management approaches. The pathogenesis of OA involves complex interactions between mechanical stress, inflammatory mediators, and metabolic dysfunction, leading to progressive cartilage degradation and structural joint alterations. Major risk factors include advancing age, obesity, joint injuries, genetic predisposition, and occupational hazards. Current evidence suggests that early intervention through lifestyle modifications, appropriate physical activity, and weight management can significantly delay disease progression. Management strategies encompass both non-pharmacological interventions such as exercise therapy and weight reduction, alongside pharmacological treatments including analgesics and disease-modifying agents. This review synthesizes recent research findings to provide healthcare professionals with an evidence-based framework for understanding, preventing, and managing osteoarthritis in clinical practice.

Keywords: Osteoarthritis, cartilage degradation, joint inflammation, risk factors, disease management, prevention strategies, pathophysiology

How to cite this article: Singh A, Singh A. Osteoarthritis: a comprehensive review of pathophysiology, risk factors, prevention, and management. Int J Drug Deliv Technol. 2026;16(73s): 596-606. DOI: 10.25258/ijddt.16.73s.66

1. INTRODUCTION

Osteoarthritis stands as the most common form of arthritis globally, affecting approximately 240 million people worldwide and representing a leading cause of disability among older adults (Hunter & Bierma-Zeinstra, 2019). Unlike other arthritic conditions, OA primarily manifests as a degenerative disorder characterized by progressive breakdown of articular cartilage, subchondral bone remodeling, and synovial inflammation. The disease predominantly affects weight-bearing joints including the knees, hips, and spine, though it can also impact hands and other joints (Martel-Pelletier et al., 2016).

The global prevalence of osteoarthritis continues to rise dramatically, driven primarily by population aging and increasing rates of obesity across developed and developing nations. Current epidemiological data suggests that by 2050, over 130 million individuals will suffer from OA worldwide, with knee OA alone affecting more than 250 million people (Cui et al., 2020). This escalating prevalence translates into enormous healthcare expenditures, lost productivity, and diminished quality of life for affected individuals.

Despite its widespread impact, osteoarthritis has historically been viewed as an inevitable consequence of aging, a perspective that undermined research efforts and therapeutic development for decades. However, contemporary understanding recognizes OA as a complex, multifactorial disease involving intricate biological, mechanical, and metabolic processes (Abramoff & Caldera, 2020). This paradigm shift has catalyzed intensive research into disease mechanisms and novel therapeutic targets.

The clinical presentation of osteoarthritis typically includes joint pain, stiffness particularly after periods of inactivity, reduced range of motion, and eventual functional impairment. These symptoms progress gradually, often over years or decades, making early

detection and intervention challenging yet critically important. Understanding the underlying mechanisms driving OA progression has become essential for developing effective preventive strategies and treatments.

This review aims to provide a comprehensive examination of osteoarthritis, synthesizing current knowledge regarding its pathophysiological basis, identifying modifiable and non-modifiable risk factors, exploring evidence-based prevention approaches, and evaluating contemporary management strategies. By integrating recent research findings with clinical perspectives, this work seeks to enhance understanding of OA and inform evidence-based practice for healthcare professionals managing this challenging condition.

2. OBJECTIVES

The primary objectives of this comprehensive review are:

1. To elucidate the complex pathophysiological mechanisms underlying osteoarthritis development and progression, including cartilage degradation, inflammatory processes, and metabolic dysfunction
2. To identify and evaluate both modifiable and non-modifiable risk factors contributing to OA susceptibility and disease progression
3. To examine evidence-based prevention strategies that can delay onset or slow progression of osteoarthritis in at-risk populations
4. To analyze current management approaches, encompassing both non-pharmacological and pharmacological interventions, based on contemporary clinical evidence
5. To synthesize recent research findings to provide healthcare professionals with practical insights for improving patient outcomes in osteoarthritis care

3. SCOPE OF STUDY

This review encompasses the following defined parameters:

- **Disease Focus:** Primary osteoarthritis affecting major joints (knee, hip, hand, spine), excluding secondary OA due to specific systemic diseases
- **Literature Coverage:** Research publications from 2015-2024, emphasizing recent advances while incorporating seminal earlier works where foundational
- **Geographical Scope:** Global perspective incorporating epidemiological data and research from diverse populations across continents
- **Target Population:** Adult populations aged 40 years and above, representing primary OA demographics
- **Intervention Focus:** Conservative management and established pharmacological therapies; surgical interventions discussed briefly as advanced options
- **Exclusions:** Rare OA variants, purely surgical management protocols, experimental therapies not yet validated in clinical trials

4. PATHOPHYSIOLOGY OF OSTEOARTHRITIS

The pathophysiology of osteoarthritis involves a complex cascade of biological events affecting multiple joint tissues, fundamentally challenging the traditional view of OA as simply "wear and tear" arthritis. Contemporary research reveals OA as an active disease process involving the entire joint organ, including articular cartilage, subchondral bone, synovium, ligaments, and periarticular muscles (Martel-Pelletier et al., 2016).

4.1 Cartilage Degradation

Articular cartilage degradation represents the hallmark feature of osteoarthritis. Healthy cartilage consists of a highly organized extracellular matrix composed primarily of type II collagen and proteoglycans, particularly aggrecan, which provide tensile strength and compressive resistance respectively (Abramoff & Caldera, 2020). In OA, this delicate balance becomes disrupted as chondrocytes, the sole cell type within cartilage, undergo phenotypic changes and produce excessive degradative enzymes.

The degradation process begins when mechanical stress or biochemical factors trigger chondrocytes to increase production of matrix metalloproteinases (MMPs) and aggrecanases, collectively known as ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs) (Martel-Pelletier et al., 2016). These enzymes break down collagen and proteoglycans faster than chondrocytes can synthesize new matrix components, leading to progressive cartilage thinning and loss of biomechanical properties.

4.2 Inflammatory Mediators

While osteoarthritis lacks the systemic inflammation characteristic of rheumatoid arthritis, local inflammatory processes play crucial roles in disease progression. The synovial membrane becomes

activated, producing pro-inflammatory cytokines including interleukin-1 beta (IL-1β), tumor necrosis factor-alpha (TNF-α), and interleukin-6 (IL-6) (Hunter & Bierma-Zeinstra, 2019). These mediators create a self-perpetuating inflammatory cycle, stimulating further production of degradative enzymes and inhibiting matrix synthesis.

Recent research has identified the complement system and inflammasome activation as additional inflammatory pathways contributing to OA pathogenesis (Kloppenburg & Berenbaum, 2020). The NLRP3 inflammasome, activated by cartilage breakdown products and mechanical stress, promotes IL-1β production and chondrocyte apoptosis, accelerating joint destruction.

4.3 Subchondral Bone Remodeling

Subchondral bone undergoes significant pathological changes in osteoarthritis, transitioning from early-stage bone loss to later sclerosis and osteophyte formation. Abnormal mechanical loading triggers increased bone turnover, with osteoclast and osteoblast activity becoming dysregulated (Cui et al., 2020). This remodeling alters the biomechanical properties of subchondral bone, reducing its capacity to absorb shock and transferring excessive stress to overlying cartilage.

Microfractures and bone marrow lesions frequently develop in subchondral bone, correlating strongly with pain severity and disease progression. These lesions contain inflammatory infiltrates and nerve growth factor, contributing to the pain experience in OA patients (Kloppenburg & Berenbaum, 2020).

4.4 Metabolic and Molecular Mechanisms

Emerging evidence highlights metabolic dysfunction as a key driver of OA pathogenesis, particularly in obesity-related cases. Adipose tissue produces adipokines such as leptin and adiponectin, which directly influence cartilage metabolism and promote inflammatory responses (Francisco et al., 2018). Metabolic syndrome components including dyslipidemia, hypertension, and insulin resistance associate independently with OA risk, suggesting systemic metabolic factors influence local joint pathology.

At the molecular level, altered cellular signaling pathways including Wnt, Notch, and transforming growth factor-beta (TGF-β) contribute to abnormal chondrocyte differentiation and matrix production. Epigenetic modifications, including DNA methylation and histone acetylation, regulate gene expression patterns that perpetuate the OA phenotype across cell generations (Abramoff & Caldera, 2020).



Figure 1: Pathophysiological Cascade in Osteoarthritis Development

5. RISK FACTORS FOR OSTEOARTHRITIS

Understanding risk factors for osteoarthritis enables identification of at-risk individuals and development of targeted prevention strategies. Risk factors are categorized as non-modifiable and modifiable, with many demonstrating complex interactions.

5.1 Non-Modifiable Risk Factors

Age represents the strongest risk factor for osteoarthritis, with prevalence increasing dramatically after age 50. Approximately 10% of men and 18% of women over 60 have symptomatic OA (Hunter & Bierma-Zeinstra, 2019). Age-related changes include

decreased chondrocyte proliferative capacity, accumulated oxidative damage, reduced proteoglycan synthesis, and impaired repair mechanisms.

Sex influences OA susceptibility, with women experiencing higher rates than men, particularly after menopause. Hormonal factors, specifically declining estrogen levels, contribute to this disparity (Martel-Pelletier et al., 2016). Women also demonstrate different biomechanical patterns and joint anatomy that may increase susceptibility.

Genetics account for 40-70% of OA susceptibility depending on joint site (Kloppenburg & Berenbaum, 2020). Genome-wide association studies have identified over 90 genetic loci associated with OA risk, affecting genes involved in cartilage development, inflammation, and bone metabolism. Family history of OA significantly increases individual risk.

Race and Ethnicity show variable OA patterns, with African Americans demonstrating higher knee OA prevalence but lower hip OA rates compared to Caucasians. Asian populations show distinct patterns with higher hand and knee OA but lower hip OA (Cui et al., 2020).

5.2 Modifiable Risk Factors

Obesity ranks among the most significant modifiable risk factors, increasing OA risk through both mechanical loading and metabolic pathways. Each 5-unit increase in body mass index (BMI) associates with approximately 35% increased knee OA risk (Francisco et al., 2018). Adipose tissue produces inflammatory mediators that systemically influence joint health, explaining obesity's association with hand OA despite minimal mechanical loading.

Joint Injury dramatically increases subsequent OA risk, with anterior cruciate ligament tears increasing knee OA likelihood by 5-6 fold (Hunter & Bierma-Zeinstra, 2019). Meniscal injuries, fractures involving articular surfaces, and joint dislocations similarly predispose to OA development, often manifesting within 10-20 years post-injury.

Occupational Factors involving repetitive joint loading significantly elevate OA risk. Occupations requiring frequent kneeling, squatting, or heavy lifting increase knee OA risk by 2-3 fold (Kloppenburg & Berenbaum, 2020). Construction workers, farmers, and professional athletes demonstrate elevated OA rates in joints subject to occupational stress.

Physical Activity Patterns show a complex relationship with OA. While moderate regular exercise protects against OA through maintenance of muscle strength and joint stability, excessive high-impact activity increases risk (Weng et al., 2023). Elite athletes in high-impact sports demonstrate substantially elevated OA rates.

Dietary Factors emerging research suggests certain dietary patterns influence OA risk. Mediterranean diets rich in omega-3 fatty acids, antioxidants, and anti-inflammatory compounds may reduce OA progression (Thomas et al., 2018). Vitamin D deficiency correlates with increased OA severity and progression.

Muscle Weakness particularly quadriceps weakness in knee OA, both predisposes to disease development and accelerates progression. Reduced muscle strength compromises joint stability and shock absorption, increasing cartilage stress (Abramoff & Caldera, 2020).

Table 1: Major Risk Factors for Osteoarthritis and Their Relative Impact

Risk Factor	Category	Relative Risk/Odds Ratio	Primary Affected Joints	Modifiable
Age >60 years	Demographic	OR: 3.5-5.0	All joints	No
Female sex (post-menopause)	Demographic	OR: 1.5-2.0	Knee, hand	No
Obesity (BMI >30)	Metabolic	OR: 2.5-4.0	Knee, hip, hand	Yes
Previous joint injury	Traumatic	OR: 5.0-6.0	Site-specific	Partially
Genetic predisposition	Hereditary	OR: 2.0-3.0	All joints	No
Occupational loading	Mechanical	OR: 2.0-3.5	Knee, hip	Yes
Muscle weakness	Functional	OR: 1.8-2.5	Knee, hip	Yes
High-impact sports	Activity	OR: 2.5-5.0	Site-specific	Yes
Metabolic syndrome	Metabolic	OR: 1.5-2.2	Multiple joints	Yes
Vitamin D deficiency	Nutritional	OR: 1.3-1.8	Knee, hip	Yes

Note: OR = Odds Ratio; BMI = Body Mass Index. Relative risks vary by study population and joint site. Data synthesized from multiple sources (Hunter & Bierma-Zeinstra, 2019; Kloppenburg & Berenbaum, 2020; Cui et al., 2020).

6. PREVENTION STRATEGIES

Effective prevention of osteoarthritis targets modifiable risk factors through lifestyle interventions and protective behaviors, with strongest evidence supporting weight management and appropriate physical activity.

6.1 Weight Management

Weight reduction represents the most effective preventive strategy for obese individuals at OA risk. Studies demonstrate that each kilogram of weight loss reduces knee joint loading by approximately 4 kilograms during walking (Messier et al., 2021). Even modest weight loss of 5-10% body weight significantly reduces OA incidence and slows progression in established disease. Comprehensive weight management programs combining dietary modification with increased physical activity show superior outcomes compared to diet or exercise alone.

6.2 Exercise and Physical Activity

Regular moderate-intensity exercise protects against OA development through multiple mechanisms including maintenance of healthy cartilage metabolism, preservation of muscle strength, enhancement of joint stability, and weight control (Weng et al., 2023). Recommended activities include low-impact aerobic exercises such as swimming, cycling, and walking, combined with resistance training to strengthen periarticular muscles. Exercise programs should be individualized, progressive, and sustainable, avoiding excessive high-impact activities that may accelerate cartilage breakdown.

6.3 Injury Prevention

Preventing joint injuries significantly reduces subsequent OA risk, particularly in young active individuals. Strategies include proper training techniques, appropriate protective equipment during sports, neuromuscular training programs to enhance joint stability, and prompt appropriate treatment of injuries when they occur (Hunter & Bierma-Zeinstra, 2019). Anterior cruciate ligament injury prevention programs have demonstrated effectiveness in reducing injury rates by 50% or more in high-risk sports.

6.4 Occupational Modifications

Workplace interventions reducing repetitive joint loading include ergonomic adjustments, job rotation, mechanical aids for heavy lifting, and provision of kneeling pads or supportive equipment (Kloppenburg & Berenbaum, 2020). Workers in high-risk occupations benefit from education regarding proper body mechanics and joint protection techniques.

6.5 Nutritional Approaches

While no specific diet prevents OA definitively, anti-inflammatory dietary patterns may reduce risk. Mediterranean diets rich in fruits, vegetables, whole grains, fish, and healthy fats show promise in reducing inflammatory markers associated with OA (Thomas et al., 2018). Adequate vitamin D and calcium intake support bone health and may influence OA development. Omega-3 fatty acid supplementation demonstrates modest anti-inflammatory effects potentially beneficial for joint health.



Figure 2: Evidence-Based Prevention Strategies for Osteoarthritis

7. MANAGEMENT OF OSTEOARTHRITIS

Osteoarthritis management adopts a multimodal approach combining non-pharmacological and pharmacological interventions tailored to disease severity, patient characteristics, and individual preferences. Current guidelines emphasize non-pharmacological therapies as first-line treatment, with medications providing adjunctive symptom relief.

7.1 Non-Pharmacological Management

Exercise Therapy forms the cornerstone of OA management, with strong evidence supporting its effectiveness in reducing pain and improving function (Weng et al., 2023). Therapeutic exercise programs should include aerobic conditioning, muscle strengthening particularly of periarticular muscles, and flexibility exercises. Aquatic therapy offers particular benefits for patients with severe OA by reducing joint loading while maintaining exercise intensity.

Weight Loss in overweight or obese patients produces substantial clinical benefits, with studies showing that 10% weight reduction reduces knee OA pain by approximately 50% and significantly improves physical function (Messier et al., 2021). Combined diet and exercise interventions demonstrate superior outcomes compared to either approach alone.

Physical Therapy encompasses various modalities including manual therapy, therapeutic ultrasound, transcutaneous electrical nerve stimulation (TENS), and heat/cold therapy. While evidence quality varies, individualized physical therapy programs combining multiple modalities show consistent benefits for pain relief and functional improvement (Kolasinski et al., 2020).

Assistive Devices including canes, walkers, shoe inserts, and knee braces reduce joint loading and improve stability. Lateral wedge insoles for medial compartment knee OA and walking aids for hip OA demonstrate modest benefits in selected patients (Kloppenburg & Berenbaum, 2020).

Education and Self-Management programs teaching patients about OA pathophysiology, treatment options, and self-care strategies significantly improve outcomes. Structured self-management programs reduce pain and healthcare utilization while enhancing patient confidence and adherence to treatment recommendations (Hunter & Bierma-Zeinstra, 2019).

7.2 Pharmacological Management

Acetaminophen (Paracetamol) represents a commonly recommended first-line oral analgesic for mild OA pain due to its favorable safety profile. However, recent evidence suggests limited efficacy, with effect sizes smaller than previously believed (Kolasinski et al., 2020). Maximum recommended dosage is 3-4 grams daily, with caution in patients with hepatic impairment.

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) demonstrate superior efficacy to acetaminophen for OA pain relief, available in both oral and topical formulations. Topical NSAIDs offer comparable efficacy to oral formulations for knee and hand OA with substantially reduced systemic adverse effects (Kloppenburg & Berenbaum, 2020). Oral NSAIDs require cautious use in elderly patients and

those with cardiovascular, renal, or gastrointestinal risk factors.

Intra-Articular Corticosteroids provide short-term pain relief lasting 4-8 weeks in responsive patients, particularly useful for acute flares or as a bridge to other interventions (Kolasinski et al., 2020). Repeated frequent injections may accelerate cartilage loss and are generally limited to 3-4 times annually per joint.

Intra-Articular Hyaluronic Acid shows modest benefits for knee OA in some patients, though efficacy remains controversial with conflicting evidence from clinical trials. When effective, benefits typically persist for 3-6 months (Hunter & Bierma-Zeinstra, 2019). Patient selection and product characteristics influence outcomes.

Duloxetine a serotonin-norepinephrine reuptake inhibitor, demonstrates efficacy for OA pain management, particularly in patients with central pain sensitization or comorbid depression (Kolasinski et al., 2020). Typical dosing is 30-60 mg daily with gradual titration to minimize side effects.

Opioid Analgesics should be reserved for severe pain refractory to other treatments due to limited efficacy, substantial adverse effects, and addiction potential. When necessary, use should be time-limited with regular reassessment (Kloppenburg & Berenbaum, 2020).

Glucosamine and Chondroitin popular dietary supplements with controversial evidence. While some studies suggest modest symptomatic benefits, high-quality trials show inconsistent results (Thomas et al., 2018). These supplements appear safe with minimal adverse effects for patients choosing to try them.

7.3 Surgical Interventions

Joint Replacement (Arthroplasty) represents definitive treatment for severe OA with intractable pain and functional impairment unresponsive to conservative management. Total knee and hip replacements demonstrate excellent long-term outcomes with substantial pain reduction and functional restoration (Hunter & Bierma-Zeinstra, 2019). Contemporary prostheses show 90-95% survival rates at 15-20 years.

Arthroscopic Procedures including debridement and lavage show limited benefit for degenerative knee OA without mechanical symptoms, with current guidelines generally recommending against these procedures (Kolasinski et al., 2020).

Osteotomy realigns weight-bearing axes in selected younger patients with unicompartmental OA, potentially delaying need for joint replacement by 5-10 years (Kloppenburg & Berenbaum, 2020).

Table 2: Comparative Effectiveness of OA Management Interventions

Intervention	Evidence Level	Pain Reduction (0-10 scale)	Function Improvement	Onset of Effect	Duration of Benefit	Safety Profile
Exercise therapy	Strong (A)	1.5-2.5	Moderate to Large	4-8 weeks	Ongoing with adherence	Excellent
Weight loss (≥10%)	Strong (A)	2.0-3.0	Large	8-16 weeks	Sustained with maintenance	Excellent
Topical NSAIDs	Strong (A)	1.5-2.0	Moderate	1-2 weeks	During use	Excellent
Oral NSAIDs	Strong (A)	2.0-2.5	Moderate	1-2 weeks	During use	Moderate concerns
Acetaminophen	Moderate (B)	0.5-1.0	Minimal	1 week	During use	Good
IA corticosteroids	Moderate (B)	1.5-2.5	Moderate	3-7 days	4-8 weeks	Good
IA hyaluronic acid	Weak to Moderate (B-C)	1.0-1.5	Minimal to Moderate	2-4 weeks	3-6 months	Excellent
Duloxetine	Moderate (B)	1.5-2.0	Moderate	4-8 weeks	During use	Moderate
Physical therapy	Moderate (B)	1.0-2.0	Moderate	4-6 weeks	Variable	Excellent

Total joint replacement	Strong (A)	5.0-7.0	Very Large	Immediate post-recovery	15-20+ years	Moderate (surgical risks)

Note: Evidence levels based on systematic reviews and clinical guidelines. Pain reduction represents average improvement on 10-point scale. IA = Intra-articular. Data synthesized from Kolasinski et al. (2020), Hunter & Bierma-Zeinstra (2019), and Kloppenburg & Berenbaum (2020).



Figure 3: Stepwise Treatment Algorithm for Osteoarthritis Management

8. EMERGING THERAPIES AND FUTURE DIRECTIONS

Research into disease-modifying osteoarthritis drugs (DMOADs) continues intensively, though no agents have yet achieved regulatory approval. Promising approaches under investigation include anti-cytokine therapies targeting IL-1 and TNF-α, inhibitors of cartilage-degrading enzymes, and agents promoting cartilage regeneration (Kloppenburg & Berenbaum, 2020).

Cell-based therapies including platelet-rich plasma (PRP) and mesenchymal stem cells show promise in preclinical and early clinical studies, though evidence remains insufficient for routine clinical recommendation (Hunter & Bierma-Zeinstra, 2019). Continued investigation may clarify optimal patient selection, treatment protocols, and long-term efficacy.

Precision medicine approaches leveraging genetic, metabolic, and imaging biomarkers may enable personalized OA treatment strategies targeting specific disease endotypes. Advanced imaging techniques including compositional MRI and molecular imaging may facilitate early OA detection and monitoring of therapeutic responses (Martel-Pelletier et al., 2016).

Digital health technologies including wearable sensors, smartphone applications, and telehealth platforms increasingly support OA self-management, exercise adherence, and remote monitoring. Integration of artificial intelligence may enhance diagnostic accuracy and treatment optimization (Weng et al., 2023).

Table 3: Emerging Therapeutic Approaches in Osteoarthritis Research

Therapeutic Approach	Mechanism of Action	Development Stage	Preliminary Evidence	Key Challenges
Anti-IL-1 biologics	Block inflammatory cytokine IL-1	Phase II/III trials	Modest structural	Identifying responders, cost

			benefits, variable symptoms	
ADAMTS-5 inhibitors	Prevent cartilage degradation	Phase II trials	Reduced cartilage loss in trials	Long-term safety, efficacy
Wnt pathway inhibitors	Modulate bone/cartilage signaling	Preclinical/Phase I	Promising preclinical data	Translation to humans
Senolytic agents	Remove senescent cells	Preclinical	Reduced OA features in mice	Human translation pending
Platelet-rich plasma (PRP)	Growth factor delivery	Clinical use, mixed evidence	Inconsistent results, some benefit	Standardization, placebo effects
Mesenchymal stem cells	Regenerative/anti-inflammatory	Early clinical trials	Safety established, efficacy unclear	Optimal protocols, cost
Gene therapy	Deliver therapeutic genes to joints	Preclinical	Proof of concept in animals	Delivery methods, safety
Nerve growth factor (NGF) antibodies	Block pain signaling	Phase III (development halted)	Effective analgesia	Adverse events, regulatory concerns

Note: Development stages and evidence current as of 2024. Clinical availability and regulatory status subject to change. Data from Kloppenburg & Berenbaum (2020), Hunter & Bierma-Zeinstra (2019), and recent clinical trial databases.

9. DISCUSSION

This comprehensive review synthesizes current understanding of osteoarthritis pathophysiology, risk factors, prevention, and management, revealing both substantial progress and remaining challenges in addressing this prevalent condition. The evolving conceptualization of OA from simple mechanical "wear and tear" to a complex metabolic and inflammatory disease has opened new avenues for therapeutic development while underscoring the multifactorial nature of effective management.

The pathophysiological insights reviewed here demonstrate that OA involves coordinated dysfunction across cartilage, bone, synovium, and other joint tissues, driven by mechanical, inflammatory, and metabolic factors. This understanding suggests that optimal interventions must address multiple pathogenic pathways rather than targeting isolated mechanisms. The identification of inflammatory mediators, metabolic dysfunction, and altered signaling pathways as disease drivers positions OA within the broader context of chronic inflammatory and metabolic diseases, potentially enabling application of therapeutic strategies developed for related conditions.

Risk factor analysis reveals obesity as perhaps the most critical modifiable risk factor, operating through both mechanical and metabolic mechanisms. The strong association between obesity and OA across multiple joint sites, including non-weight-bearing joints, highlights the systemic metabolic contribution to disease pathogenesis (Francisco et al., 2018). This finding emphasizes weight management not merely as symptomatic treatment but as genuine disease modification. The challenge remains translating this knowledge into effective population-level interventions, as obesity rates continue rising globally.

Current prevention and management approaches demonstrate clear efficacy, particularly for non-pharmacological interventions including exercise and weight loss. The evidence supporting these interventions as first-line treatments is robust and consistent across multiple systematic reviews and clinical trials (Kolasinski et al., 2020). However, real-world implementation faces substantial barriers including patient adherence, access to supervised programs, and healthcare system capacity to deliver intensive lifestyle interventions. Addressing these implementation challenges represents a critical priority for improving OA outcomes at the population level.

Pharmacological management options provide symptomatic relief but lack disease-modifying capabilities, highlighting a major unmet need in OA therapeutics. While NSAIDs, corticosteroids, and emerging agents like duloxetine offer pain reduction, no currently available medication slows structural

disease progression (Hunter & Bierma-Zeinstra, 2019). The development of effective DMOADs remains a top research priority, though previous attempts have largely failed in late-stage clinical trials. This failure may reflect disease heterogeneity, with different patients exhibiting distinct disease endotypes requiring personalized therapeutic approaches.

Several limitations characterize current OA research and management. Most therapeutic trials focus on knee OA, with less evidence for hip, hand, and other joint sites. Sex and ethnic disparities in OA prevalence and outcomes remain incompletely understood, potentially reflecting both biological differences and differential access to care. Long-term outcomes from emerging therapies like PRP and stem cells require further investigation in rigorous controlled trials. Additionally, most evidence derives from populations in high-income countries, with less data from developing regions where OA burden is rising rapidly.

The healthcare system and economic implications of OA deserve emphasis, as rising prevalence translates into enormous costs from medical care, lost productivity, and disability (Cui et al., 2020). Total joint replacements, while highly effective for severe OA, represent expensive interventions with healthcare systems in many countries facing capacity constraints to meet growing demand. This reality underscores the importance of prevention and early intervention to delay or avoid progression to end-stage disease requiring surgery.

Future research should prioritize several key areas: identification of biomarkers enabling early diagnosis and prediction of disease progression; development of true disease-modifying therapies addressing underlying pathophysiology; investigation of combination interventions addressing multiple pathogenic pathways simultaneously; understanding mechanisms underlying pain in OA to develop targeted analgesic strategies; and implementation research optimizing delivery of evidence-based interventions in real-world settings. Precision medicine approaches leveraging genetic, metabolic, and imaging data may enable personalized treatment selection, matching specific therapies to patients most likely to benefit (Martel-Pelletier et al., 2016).



Figure 4: Integrated Model of OA Pathogenesis, Risk Factors, and Management Approaches

10. CONCLUSION

Osteoarthritis represents a complex, multifactorial degenerative joint disease affecting hundreds of millions worldwide, with prevalence projected to increase substantially in coming decades due to population aging and rising obesity rates. This comprehensive review has examined the intricate pathophysiology underlying OA, involving cartilage degradation, inflammatory processes, subchondral bone remodeling, and metabolic dysfunction that together drive progressive joint destruction and pain.

Understanding of OA has evolved dramatically from simplistic mechanical wear models to recognition of OA as an active disease process involving multiple tissues and biological pathways. This paradigm shift has identified numerous potential therapeutic targets, though translation to effective disease-modifying treatments remains elusive. Current management relies primarily on non-pharmacological interventions including exercise, weight loss, and physical therapy, which demonstrate robust evidence for improving symptoms and function.

Pharmacological options provide symptomatic relief but lack disease-modifying capabilities, with joint replacement surgery remaining the definitive treatment for severe refractory OA. Prevention strategies targeting modifiable risk factors, particularly obesity and joint injury, offer the best opportunity for reducing OA burden at the population level.

Future progress requires continued research into disease mechanisms, development of effective DMOADs, implementation of precision medicine approaches enabling personalized treatment selection, and healthcare system innovations supporting delivery of evidence-based interventions. For clinicians, optimal OA management involves early identification of at-risk individuals, aggressive intervention on modifiable risk factors, multimodal treatment combining proven therapies, and appropriate timing of referral for advanced interventions including surgery.

Ultimately, addressing the growing OA epidemic will require coordinated efforts spanning basic science research, clinical trial innovation, public health prevention initiatives, healthcare delivery optimization, and policy changes supporting access to effective treatments. While challenges remain substantial, the knowledge base reviewed here provides a strong foundation for evidence-based clinical practice and continued therapeutic advances that may eventually transform OA from a chronic progressive condition to a preventable and modifiable disease.

REFERENCES

1. Abramoff, B. & Caldera, F.E. (2020) 'Osteoarthritis: Pathology, diagnosis, and treatment options', Medical Clinics of North America, 104(2), pp. 293-311.
2. Cui, A., Li, H., Wang, D., Zhong, J., Chen, Y. & Lu, H. (2020) 'Global, regional prevalence, incidence and risk factors of knee osteoarthritis in population-based studies', EClinicalMedicine, 29-30, pp. 100587.
3. Francisco, V., Pérez, T., Pino, J., López, V., Franco, E., Alonso, A., Gonzalez-Gay, M.A., Mera, A., Lago, F., Gómez, R. & Gualillo, O. (2018) 'Biomechanics, obesity, and osteoarthritis: The role of adipokines: When the levee breaks', Journal of Orthopaedic Research, 36(2), pp. 594-604.
4. Hunter, D.J. & Bierma-Zeinstra, S. (2019) 'Osteoarthritis', The Lancet, 393(10182), pp. 1745-1759.
5. Kloppenburg, M. & Berenbaum, F. (2020) 'Osteoarthritis year in review 2019: epidemiology and therapy', Osteoarthritis and Cartilage, 28(3), pp. 242-248.
6. Kolasinski, S.L., Neogi, T., Hochberg, M.C., Oatis, C., Guyatt, G., Block, J., Callahan, L., Copenhaver, C., Dodge, C., Felson, D., Gellar, K., Harvey, W.P., Hawker, G., Herzig, E., Kwoh, C.K., Nelson, A.E., Samuels, J., Scanzello, C., White, D., Wise, B., Altman, R.D., DiRenzo, D., Fontanarosa, J., Giradi, G., Ishimori, M., Misra, D., Shah, A.A., Shmagel, A.K., Thoma, L.M., Turgunbaev, M., Turner, A.S. & Reston, J. (2020) '2019 American College of Rheumatology/Arthritis Foundation guideline for the management of osteoarthritis of the hand, hip, and knee', Arthritis & Rheumatology, 72(2), pp. 220-233.
7. Martel-Pelletier, J., Barr, A.J., Cicuttini, F.M., Conaghan, P.G., Cooper, C., Goldring, M.B., Goldring, S.R., Jones, G., Teichtahl, A.J. & Pelletier, J.P. (2016) 'Osteoarthritis', Nature Reviews Disease Primers, 2, pp. 16072.
8. Messier, S.P., Mihalko, S.L., Beavers, D.P., Nicklas, B.J., DeVita, P., Carr, J.J., Hunter, D.J., Lyles, M., Guermazi, A., Bennell, K.L. & Loeser, R.F. (2021) 'Effect of high-intensity strength training on knee pain and knee joint compressive forces among adults with knee osteoarthritis: The START randomized clinical trial', JAMA, 325(7), pp. 646-657.
9. Thomas, S., Browne, H., Mobasheri, A. & Rayman, M.P. (2018) 'What is the evidence for a role for diet and nutrition in osteoarthritis?', Rheumatology, 57(suppl_4), pp. iv61-iv74.
10. Weng, Q., Goh, S.L., Wu, J., Persson, M.S.M., Wei, J., Sarmanova, A., Li, X., Hall, M., Doherty, M. & Zhang, W. (2023) 'Comparative efficacy of exercise therapy and oral non-steroidal anti-inflammatory drugs and paracetamol for knee or hip osteoarthritis: a network meta-analysis of randomised controlled trials', British Journal of Sports Medicine, 57(16), pp. 1056-1063.